Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Phase 1
20
about 3.2 years
18+
1 site in CA
What this study is about
This trial is testing if zirconium (Zr)-89 crefmirlimab berdoxam, a radioactive drug that targets immune cells, combined with immuno-positron emission tomography (PET) imaging can better identify areas of immune cell activity in patients with resectable brain tumors. The goal is to improve the accuracy of determining how well these patients will respond to cancer immunotherapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Electronic Health Record Review
- 2.Undergo Advanced Magnetic Resonance Imaging
- 3.Undergo Brain Surgery
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events
imaging, surgery, biopsy
Oncology